Stella Shi has profound investment and management experience in the biopharmaceutical industry in China and the US. She has paved the way to drive the investment, incubation, acceleration and strategic management of China's first batch unicorn biopharmaceutical companies, including Burning Rock (NASDAQ:BNR), YHL Diagnostic (688575), InventisBio (688382), Keymed Bio (HK'02162), New Horizon health (HK'06606), Xihua Science, Regor Therapeutics, Geneseeq, Singleron Diagnostics, Pinnacle Diagnostics, Guangzhou LuPeng, Repare Therapeutics (NASDAQ:RPTX), Revolution Medicine (NASDAQ:RVMD), KSQ Therapeutics and others.
In the past decade, Stella Shi has accumulated global vision and outstanding biopharmaceutical industry insights. Prior to joining LAV, Ms. Shi was the Head of New Product Strategy for Roche's Asia Pacific Oncology business division and a consultant at ZS Associates. Ms. Shi holds a Bachelor's degree in Biology from Fudan University.